Very low-carbohydrate ketogenic diet in treatment-naïve women with endometrial cancer and overweight: a randomized feasibility study

This multicenter, prospective, randomized controlled trial (NCT03285152) evaluates the primary endpoint of feasibility of a very-low carbohydrate diet (VLCD) in 19 women with obesity/overweight and endometrial cancer, who are randomized 2:1 to either a VLCD or a standard diet for 21–28 days. Fifteen participants complete the study, with 91 ± 4% of VLCD meals consumed, 5.5 ± 0.8% weight lost, and no grade 3/4 adverse events. Secondary endpoints include assessments of tumor biology and circulating metabolic biomarkers. Fasting glucose and insulin fall 22 ± 5.9% and 60 ± 3.8%, while total cholesterol and low-density lipoprotein (LDL) rise 6 ± 2.7% and 17.8 ± 8.9%. In a pre-specified exploratory outcome, RNA-Seq shows enrichment of CD8 + T-cells (q < 0.034; NES > 1.75), confirmed by immunohistochemistry (IHC) showing CD8 + T-cells infiltration of the tumor margins (q = 0.034; NES = 1.75). We conclude that VLCD is feasible and well-tolerated. Dietary interventions have been proposed as potential therapeutic strategies in cancer. Here, the authors report a feasibility randomized clinical trial comparing standard diet with a very lowcarbohydrate ketogenic diet (VLCD) in treatment-naive women with endometrial cancer and obesity or overweight.

Authors

Institutions

Publication Details

Journal
Nature Communications
Published
2026-05-27
DOI
https://doi.org/10.1038/s41467-026-73519-w
Primary Topic
Diet and metabolism studies
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Very low-carbohydrate ketogenic diet in treatment-naïve women with endometrial cancer and overweight: a randomized feasibility study

Nadeem R. Abu‐Rustum, Vania Hom, Francis N. Villamater, Kathryn Gorski et al.
Nature Communications
Diet and metabolism studies
article

Very low-carbohydrate ketogenic diet in treatment-naïve women with endometrial cancer and overweight: a randomized feasibility study

Nadeem R. Abu‐Rustum, Vania Hom, Francis N. Villamater, Kathryn Gorski, Michael Sigouros, Katie C. Hootman, Ginger J. Gardner, Andrew J. Plodkowski, Gabrielle Bennetti, Lewis C. Cantley, Olivier Elemento, Brandon M. Cuevas, Bhavani Ramesh, Maurice A. Hurd, Karen Carthew, Vicky Makker, Oliver Zivanovic, Yukio Sonoda, Marissa Mezzancello, Kaity Chang, Morgan Tomberlin, Yuan‐Shan Zhu, Alex McPherson, Jeshua Kim, Kari Hacker, Marcus D. Goncalves, Jenna Moyer, Vance Broach, Carol Aghajanian, Krysten Soldan, Gissell Botero Rodriguez, Ezequiel Dantas, John Nguyen, Benjamin D. Hopkins, Jennifer J. Mueller, Anastasia Tsomides, Mario M. Leitao, Britta Weigelt, Katherine Curran, Alexia Iasonos, Rema Rao Chaari, Erica Nagase, Hannah Price, M. Laura Martin, Lora H. Ellenson
article en

Abstract

This multicenter, prospective, randomized controlled trial (NCT03285152) evaluates the primary endpoint of feasibility of a very-low carbohydrate diet (VLCD) in 19 women with obesity/overweight and endometrial cancer, who are randomized 2:1 to either a VLCD or a standard diet for 21–28 days. Fifteen participants complete the study, with 91 ± 4% of VLCD meals consumed, 5.5 ± 0.8% weight lost, and no grade 3/4 adverse events. Secondary endpoints include assessments of tumor biology and circulating metabolic biomarkers. Fasting glucose and insulin fall 22 ± 5.9% and 60 ± 3.8%, while total cholesterol and low-density lipoprotein (LDL) rise 6 ± 2.7% and 17.8 ± 8.9%. In a pre-specified exploratory outcome, RNA-Seq shows enrichment of CD8 + T-cells (q < 0.034; NES > 1.75), confirmed by immunohistochemistry (IHC) showing CD8 + T-cells infiltration of the tumor margins (q = 0.034; NES = 1.75). We conclude that VLCD is feasible and well-tolerated. Dietary interventions have been proposed as potential therapeutic strategies in cancer. Here, the authors report a feasibility randomized clinical trial comparing standard diet with a very lowcarbohydrate ketogenic diet (VLCD) in treatment-naive women with endometrial cancer and obesity or overweight.

Nature Communications
Cleveland Clinic (US), Memorial Sloan Kettering Cancer Center (US), Harvard University (US), Cornell University (US), NYU Langone Health (US), Dana-Farber Cancer Institute (US), Weill Cornell Medicine (US)
National Institutes of Health
Openalex Percentile: Top 7%
Diet and metabolism studies
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.